Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Greenlight Biosciences, Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners across 5 distinct art units, showing broad examiner dispersion with limited technical grouping. This distribution calls for strong docket coordination across separate prosecution channels.
ANTHOPOLOS, PETER is the busiest examiner, with 1 pending matter. Counsel should review the five art-unit assignments for recurring biotechnology issues while tailoring each response to its assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.6% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| ARIETI, RUTH SOPHIA | 1 | 46.2% | +71.4% |
| ZHENG, LI | 1 | 83.5% | +13.0% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | — |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | — |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17478015 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS | ZHENG, LI | 70d overdue |
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | — |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | — |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
| 17202029 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17161641 | COMPOSITIONS AND METHODS FOR CONTROLLING ARTHROPOD PARASITE AND PEST INFESTATIONS | TRAN, CHRISTINA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1611 | 1 |
| 1636 | 1 |
| 1635 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | 1611 | §102§103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | — | Pending | May 02, 2022 |
| 17478015 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS | ZHENG, LI | 1662 | §112 | Non-Final OA | 70d overdue | Pending | Sep 17, 2021 |
| 17202029 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | DP | Non-Final OA | — | Pending | Mar 15, 2021 |
| 17161641 | COMPOSITIONS AND METHODS FOR CONTROLLING ARTHROPOD PARASITE AND PEST INFESTATIONS | TRAN, CHRISTINA L | 1637 | DP | Non-Final OA | — | Pending | Jan 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGreenlight Biosciences, Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Peter Anthopolos has the most, with 1 of Greenlight Biosciences, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
